Navigation Links
GW Pharmaceuticals Commences Phase 1 Clinical Trial of GWP42006 as a Potential Treatment for Epilepsy
Date:9/17/2013

LONDON, Sept. 18, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW") announced today it has commenced a Phase 1 clinical trial of product candidate GWP42006 for the treatment of epilepsy.  

Over the last five years, GW has conducted an extensive pre-clinical cannabinoid research program in the field of epilepsy in collaboration with the University of Reading in the United Kingdom. This research has led to the emergence of a number of promising cannabinoid therapeutic candidates showing anti-epileptic effects. GWP42006, one of the most promising of those candidates, is a non-psychoactive cannabinoid extracted from specific chemotypes of the cannabis plant which has shown the ability to treat seizures in pre-clinical models of epilepsy with significantly fewer side effects than currently approved anti-epileptic drugs1.

"We are pleased to have advanced GWP42006 to first dose in man, a significant milestone in the development of this novel product candidate. The decision to progress into Phase 1 follows several years of highly promising pre-clinical research," stated Dr. Stephen Wright, Director of Research and Development at GW. "We believe that GWP42006 has the potential to become an important advance in the treatment of epilepsy, a condition for which there remains a substantial unmet medical need."

Dr. Ben Whalley, Senior Lecturer in Pharmacology at the Reading School of Pharmacy, said, "Our research collaboration with GW over the last several years has shown that GWP42006 not only exerts significant anticonvulsant effects in a wide range of preclinical models of seizure and epilepsy but is also better tolerated compared to existing anti-epileptic drugs. It is also noteworthy that GWP42006 appears to employ a different mechanism of action to currently available anti-epileptic
'/>"/>

SOURCE GW Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Teva Pharmaceuticals Donates to the National Multiple Sclerosis Society in recognition of Jack Osbourne as He Competes on "Dancing with the Stars"
2. JHP Pharmaceuticals Enters Agreement to Produce Unique Late Stage Ophthalmic Product
3. Actinium Pharmaceuticals Appoints Kaushik J. Dave, Ph.D., MBA As President, Chief Executive Officer And Director
4. Frost & Sullivan Lauds Adcock Ingrams Capability to Innovatively Cater to the Dynamic Needs of Emerging Pharmaceuticals Markets
5. Dr. David Hangauer, Chief Scientific Officer and Co-Founder, commits his career to Kinex Pharmaceuticals
6. Access Pharmaceuticals Awarded Second European Patent for MuGard
7. Cardioxyl Pharmaceuticals Appoints Shi Yin Foo, M.D., Ph.D., As Chief Medical Officer
8. Caldera Pharmaceuticals Announces Closing of Financing
9. HedgePath Pharmaceuticals Enters into Key Collaboration with Mayne Pharma
10. Boehringer Ingelheim Expands Investigation of Interferon-free Hepatitis C Treatment Regimens to Reach More Patient Types through Presidio Pharmaceuticals Clinical Collaboration
11. Roche and Inovio Pharmaceuticals partner on Inovios prostate cancer and hepatitis B immunotherapy products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)...  Bayer HealthCare today announced that the U.S. ... company,s Biologics License Application (BLA) for BAY 81-8973, ... FDA approval of the investigational compound, proposed trade ... in children and adults. "Bayer ... hemophilia A patients who need them," said ...
(Date:3/4/2015)... LOVELAND, Colo. , March 4, 2015  Heska ... Webcast: What:Heska Corporation Invites You to Join Its Fourth ... the WebWhen:Thursday, March 5, 2015 @ 9:00 a.m. (MST) ... Q4 and Year End 2014 Earnings Call link on ... -- Simply log on to the web at the ...
(Date:3/4/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/4f69k2/negative_pressure ) ... Pressure Wound Therapy Market (Conventional and Single Use ... Growth, Trends and Forecast 2014 - 2020" ... The global negative pressure wound therapy market is ... product types the NPWT market is segmented into ...
Breaking Medicine Technology:FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 2FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 3Webcast Alert: Heska Announces Fourth Quarter and Year End 2014 Earnings Conference Call Webcast 2Global Negative Pressure Wound Therapy (Conventional and Single Use NPWT Systems) Market Report 2014-2020 2
... KANSAS CITY, Mo., Sept. 22, 2011 /PRNewswire/ -- ... benefits administrator, today announced an arrangement with Walmart to ... efforts by Argus and Walmart to provide the lowest ... agreement enables Argus to offer their customers a more ...
... The makers of the largest online network ... ( www.patientsguide.com ), announced the release of a ... - an educational resource for the aesthetic physician ... of investing in quality aesthetic medical equipment that ...
Cached Medicine Technology:Argus Announces Retail Network Relationship 2Leading Online Patient Education Resource Extends Outreach to Include Aesthetic Physician Community 2
(Date:3/4/2015)... 2015 In a small ceremony with 20 ... their new facility in New Port Richey on February 24, ... facility will allow the Florida drug detox facility ... abuse epidemic through treatment and education. “Due to our unique ... the United States, we made the decision that expanding our ...
(Date:3/4/2015)... NY (PRWEB) March 04, 2015 The ... WaterAid a total of $6.9 million, which will ... Mali, Niger and Burkina Faso. , The programs cover ... The first will focus on fixing water points in ... skills of local people to maintain water points and ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 Problem Gambling ... time to join individuals and organizations across the nation ... general public, health care professionals, policymakers, and others about ... Council on Compulsive Gambling (FCCG) and FCCG partner organizations ... to screen patients for a gambling problem, to make ...
(Date:3/4/2015)... Jose, California (PRWEB) March 04, 2015 ... CNS therapeutics market is driven by the increasing incidence ... an encouraging pipeline of late stage drugs. The unmet ... to fore the untapped potential in the market. Presently, ... effective drugs that overcome the limitations of current generation ...
(Date:3/4/2015)... 2015 Follow us on LinkedIn ... draw milk from the breast of a lactating mother through ... use for feeding the baby. Breast pumps are used when ... birth, or the mother being away from a child for ... others. Breast pumps are also used to stimulate lactation and ...
Breaking Medicine News(10 mins):Health News:Novus Medical Detox Hosts Ribbon Cutting Ceremony at Pasco County Facility 2Health News:Novus Medical Detox Hosts Ribbon Cutting Ceremony at Pasco County Facility 3Health News:Hilton Foundation Gives $6.9 Million to Sustainable Water Programs in West Africa 2Health News:Hilton Foundation Gives $6.9 Million to Sustainable Water Programs in West Africa 3Health News:Hilton Foundation Gives $6.9 Million to Sustainable Water Programs in West Africa 4Health News:Problem Gambling - A Public Health Issue; March Is Problem Gambling Awareness Month 2Health News:Rising Incidence of CNS Disorders & a Promising Global Drug Pipeline Drive the CNS Therapeutics Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Rising Incidence of CNS Disorders & a Promising Global Drug Pipeline Drive the CNS Therapeutics Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:Rising Incidence of CNS Disorders & a Promising Global Drug Pipeline Drive the CNS Therapeutics Market, According to a New Report by Global Industry Analysts, Inc. 4Health News:Increase in the Number of Nursing Mothers in the Workplace Spurs the Breast Pumps Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Increase in the Number of Nursing Mothers in the Workplace Spurs the Breast Pumps Market, According to a New Report by Global Industry Analysts, Inc. 3
... 2011 Neuralstem, Inc. (NYSE Amex: CUR) announced that ... I safety trial of Neuralstem,s human spinal cord stem ... Gehrig,s disease), and unpaid Neuralstem consultant, presented interim safety ... yesterday at the American Academy of Neurology (AAN American ...
... Balance Boards, a team of Rice University undergraduates has combined ... a computerized motion-tracking system that can enhance the progress of ... students created the new device using components of the popular ... What the kids may see as a fun video ...
... How do we assess the current and future quality of ... the April issue of Current Problems in Pediatric and ... Children and Infants with Chronic Medical Problems," presents a collection ... address one of the most contentious topics in pediatric and ...
... For the first time in a human model, scientists have ... researchers can now develop better and more efficient drugs to ... new brain cells, however, until now it was not known ... published in the journal Molecular Psychiatry , researchers from ...
... HealthDay Reporter , MONDAY, April 11 (HealthDay News) -- ... often choose a different option than they would recommend to ... who were surveyed in the research more often chose a ... repercussions, such as paralysis, than to die. But when ...
... MONDAY, April 11 (HealthDay News) -- Researchers have come up ... which patients with chronic kidney disease are more likely to ... streamline care, getting those patients who need it most the ... "The new markers provide us with an opportunity to ...
Cached Medicine News:Health News:PI presents safety results in Neuralstem ALS Stem Cell Trial 2Health News:PI presents safety results in Neuralstem ALS Stem Cell Trial 3Health News:Wii key to helping kids balance 2Health News:Wii key to helping kids balance 3Health News:How do life-threatening medical conditions in children impact quality of life? 2Health News:How do life-threatening medical conditions in children impact quality of life? 3Health News:New target for developing effective anti-depressants 2Health News:Doctors Often Wouldn't Follow Their Own Advice: Study 2Health News:Doctors Often Wouldn't Follow Their Own Advice: Study 3Health News:New Tests Could Spot Which Kidney Patients Will Do the Worst 2Health News:New Tests Could Spot Which Kidney Patients Will Do the Worst 3
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 19.0 mm and length 21 mm....
The Vitek 2 is a fully automated bacteriology system that performs bacterial identification and susceptibility testing analysis using a standard inoculum. It detects resistance and helps combat bacte...
IDS Rapid STR, a microbial identification system....
Versatrek 528 is versatile as four tests can be performed on one platform such as blood culture, sterile body fluids, mycobacteria and mycobacteria susceptibility testing. This model comes equipped w...
Medicine Products: